6533b85dfe1ef96bd12bea97

RESEARCH PRODUCT

Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction.

Giuseppina NovoSilvia SarulloCinzia NugaraFrancesco GiallauriaFilippo M. SarulloValentina AgneseGiuseppe RomanoLaura AjelloAntonino Di FrancoSalvo StornioloGiuseppa CaccamoFrancesco ClemenzaGiuseppe Vitale

subject

medicine.medical_specialtyOxygen pulselcsh:Medicineheart failure030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciences0302 clinical medicineInternal medicinemedicine030212 general & internal medicineEjection fractionbusiness.industrylcsh:RGeneral Medicinemedicine.diseaseBlood pressureValsartanHeart failuresacubitril/valsartanCardiologyexercise tolerancebusinessAnaerobic exerciseSacubitril Valsartanmedicine.drugcardiopulmonary test

description

Background. Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was shown to be superior to enalapril in reducing the risk of death and hospitalization for HF. Our aim was to evaluate the cardiopulmonary effects of sacubitril/valsartan in patients with HFrEF. Methods. We conducted an observational study. Ninety-nine ambulatory patients with HFrEF underwent serial cardiopulmonary exercise tests (CPET) after initiation of sacubitril/valsartan in addition to recommended therapy. Results. At baseline, 37% of patients had New York Heart Association (NYHA) class III. After a median follow-up of 6.2 months (range 3&ndash

yearjournalcountryeditionlanguage
2019-02-01
10.3390/jcm8020262http://hdl.handle.net/11588/743481